Medical News / Coverage ASRS 2019: Short-Term Effects of Ranibizumab Biosimilar Compared to Ranibizumab for DME

With fixed incomes a reality for many elderly patients, finding less expensive alternatives to current therapies is a hot topic for many retina specialists. Despite only being approved in India, the ranibizumab-biosimilar (Razumab) has caught the attention of many at the 2019 American Society of Retina Specialists Annual Meeting seeking an alternative treatment for patients with diabetic macular edema (DME). Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization

read more

MORE MEDICAL NEWS
Despite not being a physician, Lawrence Hoffheimer, a former healthcare attorney who practice in Washington D.C. ... read more
Heading into the 2019 American Society of Retina Specialists Annual Meeting, sessions and studies pertaining to ... read more
Results of a new study show that receiving same day intravitreal anti-VEGF treatments was highly preferred ... read more
A study presented at the 2019 American Society of Retina Specialists Annual Meeting is highlighting the ... read more